logo-loader
viewOpen Orphan PLC

Open Orphan presents at the Proactive One2One virtual conference

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual October Conference.

The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.

It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London.

Quick facts: Open Orphan PLC

Price: 25.2 GBX

AIM:ORPH
Market: AIM
Market Cap: £168.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market Report: FTSE gains as hopes rise of UK and France solving port chaos

FTSE 100 edged higher as France and the UK said they were near to ending the freight ban which has led to hundreds of lorries queuing outside Dover. London’s blue-chip index added 13 to 6,429 in spite of rising concerns over the new strain of COVID-19.   Mixed news for the UK economy...

3 weeks, 4 days ago

2 min read